ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLTX (MM)

36.01
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:CLTX NASDAQ Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 36.01 0.00 01:00:00

Calyxt Announces Upsizing and Pricing of Follow-On Offering

18/05/2018 1:50pm

Business Wire


Akari Therapeutics Plc (NASDAQ:CLTX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Akari Therapeutics Plc Charts.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) and Calyxt, Inc. (NASDAQ:CLXT) announced that the price of Calyxt’s follow-on public offering of 3,600,000 shares of Calyxt’s common stock launched May 15, 2018 has been set today at $15.00 per share, representing gross proceeds to Calyxt of $54.0 million. Due to demand, this offering was upsized from the previously announced 3,050,000 shares to accommodate Cellectis to buy 550,000 shares.

In connection with the offering, Calyxt granted the underwriters a 30-day option to purchase up to an additional 457,500 shares of Calyxt’s common stock. The closing of the offering is expected to occur on May 22, 2018, subject to customary closing conditions.

Calyxt is a consumer-centric food- and agriculture-focused company. Following the offering, Cellectis will own approximately 71.6% of Calyxt’s outstanding shares of common stock.

Citigroup, Goldman Sachs & Co. LLC and Jefferies are acting as book-running managers for the offering. Wells Fargo Securities is acting as lead manager and BMO Capital Markets Corp. is acting as co-manager.

A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on May 17, 2018. This offering will be made only by means of a prospectus. A copy of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by facsimile at (212) 902-9316, or by email at prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For CalyxtMedia contactsJennifer Moore, VP CommunicationsPhone: 917-580-1088email: media@calyxt.comorCaitlin Kasunich / Nick OpichKCSA Strategic Communications212.896.1241 / 212.896.1206email: ckasunich@kcsa.com / nopich@kcsa.comorInvestor Relations contactSimon Harnest, VP Corporate Strategy and FinancePhone: 646-385-9008email: simon.harnest@calyxt.com

1 Year Akari Therapeutics Plc Chart

1 Year Akari Therapeutics Plc Chart

1 Month Akari Therapeutics Plc Chart

1 Month Akari Therapeutics Plc Chart

Your Recent History

Delayed Upgrade Clock